Lexanopadol Hemicitrate
Lexanopadol hemicitrate is in phase II clinical trials for the treatment of pain. However there is no recent development reported.
The compound was originally developed by Gruenenthal, licensed to Forest (acquired by Actavis in 2014) in 2010.
General Information
Update Date：2016-02-01
- Drug Name：
- Lexanopadol Hemicitrate
- Research Code：
- GRT-13106G; GRT-6006
- Trade Name：
- MOA：
- Opioid receptor agonist
- Indication：
- Pain
- Status：
- Phase II (Pending)
- Company：
- Grunenthal (Originator) , Actavis
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-02-01
|
Molecular Weight | 460.52 | ||||||||||||
| Formula | C23H25FN2O • 1/2C6H8O7 | |||||||||||||
| CAS No. | 1357348-09-4 (Lexanopadol); | |||||||||||||
| Chemical Name | ||||||||||||||
| Lexanopadol （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||